CRISPR Therapeutics AG - Common Shares (CRSP) earnings
CRSP earnings moved a median of +2.57% by the close. Quarterly and annual CRSP reports and results, each read against the price at its own news timestamp. Back to the CRSP overview →
21 measured CRSP earnings events.
Where these CRSP earnings landedvs 21 measured CRSP earnings reactions
| Middle 50% of CRSP earnings reactions | -0.75% to +5.09% |
|---|---|
| Median reaction (to close) | +2.57% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 CRSP earnings events with a measured close landed between -0.75% and +5.09%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | Press release | +2.58% | +5.09% | |
| Form 10-Q CRISPR Therapeutics AG For: Jun 30 | SEC filing · Form 10-Q | +2.58% | +5.09% | |
| CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | +1.29% | -0.23% | |
| Form 10-Q CRISPR Therapeutics AG For: Mar 31 | SEC filing · Form 10-Q | +1.29% | -0.23% | |
| Form 10-K CRISPR Therapeutics AG For: Dec 31 | SEC filing · Form 10-K | +4.76% | +6.70% | |
| CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | -1.01% | -6.22% | |
| Form 10-Q CRISPR Therapeutics AG For: Sep 30 | SEC filing · Form 10-Q | -1.01% | -6.22% | |
| CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | Press release | -2.49% | +2.94% | |
| Form 10-Q CRISPR Therapeutics AG For: Jun 30 | SEC filing · Form 10-Q | -2.49% | +2.94% | |
| CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 | Press release | -2.27% | -0.75% | |
| Form 10-Q CRISPR Therapeutics AG For: Mar 31 | SEC filing · Form 10-Q | -2.27% | -0.75% | |
| Form 10-K CRISPR Therapeutics AG For: Dec 31 | SEC filing · Form 10-K | +0.55% | +6.47% | |
| CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | -1.34% | +2.57% | |
| Form 10-Q CRISPR Therapeutics AG For: Sep 30 | SEC filing · Form 10-Q | -1.34% | +2.57% | |
| CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | -4.03% | -1.75% | |
| Form 10-Q CRISPR Therapeutics AG For: Jun 30 | SEC filing · Form 10-Q | -4.03% | -1.75% | |
| CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | +2.64% | +2.98% | |
| Form 10-Q CRISPR Therapeutics AG For: Mar 31 | SEC filing · Form 10-Q | +2.64% | +2.98% | |
| Form 10-K CRISPR Therapeutics AG For: Dec 31 | SEC filing · Form 10-K | -2.78% | -0.10% | |
| CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results | Press release | +0.15% | +11.71% | |
| Form 10-Q CRISPR Therapeutics AG For: Sep 30 | SEC filing · Form 10-Q | +0.15% | +11.71% |
Keep exploring
More CRSP: analyst actions → · SEC filings → · CRSP overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Merus N.V. - Common Shares (MRUS) | 292 | +0.03% | 54% |
| Trinity Biotech plc - American Depositary Shares (TRIB) | 292 | -0.13% | 44% |
| Seres Therapeutics, Inc. (MCRB) | 290 | -0.23% | 46% |
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.